192 related articles for article (PubMed ID: 32543778)
1. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M
Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778
[TBL] [Abstract][Full Text] [Related]
2. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
[TBL] [Abstract][Full Text] [Related]
3. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
6. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults.
Lee SH; Son MH; Sung KW; Choi YB; Lee NH; Yoo KH; Koo HH; Lim DH; Shin HJ
J Neurooncol; 2014 Dec; 120(3):507-13. PubMed ID: 25108776
[TBL] [Abstract][Full Text] [Related]
8. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A
Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402
[TBL] [Abstract][Full Text] [Related]
9. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
[TBL] [Abstract][Full Text] [Related]
10. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
[TBL] [Abstract][Full Text] [Related]
11. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.
Sung KW; Lim DH; Son MH; Lee SH; Yoo KH; Koo HH; Kim JH; Suh YL; Joung YS; Shin HJ
Neuro Oncol; 2013 Mar; 15(3):352-9. PubMed ID: 23258845
[TBL] [Abstract][Full Text] [Related]
12. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
Jo JC; Kim JS; Lee JH; Lee JH; Im SN; Lee SM; Yoon SS; Kim IH; Bae SH; Lee YJ; Choi Y; Lee WS
Ann Hematol; 2021 Jan; 100(1):189-196. PubMed ID: 33205337
[TBL] [Abstract][Full Text] [Related]
13. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Ferry I; Kolesnikov-Gauthier H; Oudoux A; Cougnenc O; Schleiermacher G; Michon J; Bogart E; Chastagner P; Proust S; Valteau-Couanet D; Defachelles AS
J Pediatr Hematol Oncol; 2018 Aug; 40(6):426-432. PubMed ID: 29642099
[TBL] [Abstract][Full Text] [Related]
15. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.
Corbett R; Pinkerton R; Pritchard J; Meller S; Lewis I; Kingston J; McElwain T
Eur J Cancer; 1992; 28A(8-9):1324-8. PubMed ID: 1515243
[TBL] [Abstract][Full Text] [Related]
17. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
18. Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Grade Gliomas in Children and Adolescents.
Lee JW; Lim DH; Sung KW; Lee HJ; Yi ES; Yoo KH; Koo HH; Suh YL; Shin HJ
J Korean Med Sci; 2017 Feb; 32(2):195-203. PubMed ID: 28049229
[TBL] [Abstract][Full Text] [Related]
19.
Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
[TBL] [Abstract][Full Text] [Related]
20. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study.
Pein F; Michon J; Valteau-Couanet D; Quintana E; Frappaz D; Vannier JP; Philip T; Bergeron C; Baranzelli MC; Thyss A; Stephan JL; Boutard P; Gentet JC; Zucker JM; Tournade MF; Hartmann O
J Clin Oncol; 1998 Oct; 16(10):3295-301. PubMed ID: 9779704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]